Myeloablative reduced-toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life

. Author manuscript; available in PMC: 2014 Dec 10.

Published in final edited form as: Biol Blood Marrow Transplant. 2011 Feb 18;17(10):1490–1496. doi: 10.1016/j.bbmt.2011.02.007

Figure 2. Cumulative incidence of grade II-IV acute graft-versus-host disease (GvHD).